Physician profile
Ryan Gilbert
NPI 1255002549
$5,032.45
in general payments reported to CMS, 2019-2025
26 companies · $1,501 in 2025
The $1,501 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $735 · 2023: $1,352 · 2024: $1,445 · 2025: $1,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,199 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,198.68 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,178.61 | 2022-2025 | |
| Lilly USA, LLC | $744.20 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $440.91 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $416.69 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $370.85 | 2022-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $259.23 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $205.01 | 2023-2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $204.85 | 2022 | |
| Xeris Pharmaceuticals, INC. | $154.69 | 2022-2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.32 | 2022-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.64 | 2022-2024 | Jardiance |
| Pfizer INC. | $103.77 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $100.55 | 2023-2025 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $99.11 | 2022-2024 | |
| Viatris Specialty LLC | $93.99 | 2025 | Yupelri |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $60.04 | 2025 | |
| Shield Therapeutics INC | $56.08 | 2024 | |
| Amgen INC. | $49.67 | 2023-2025 | Evenity, Prolia |
| Mylan Specialty L.P. | $43.64 | 2024 | Yupelri |
| Hologic Sales and Service, LLC | $42.60 | 2023-2024 | Aptima |
| Currax Pharmaceuticals LLC | $31.74 | 2025 | Contrave |
| Beta Bionics, INC. | $26.32 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Janssen Pharmaceuticals, INC | $23.11 | 2022 | |
| Inspire Medical Systems, INC. | $21.38 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $20.21 | 2024 | Pifeltro, Delstrigo, Isentress |
| Almatica Pharma LLC | $17.24 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.